undamentalytics Newsletter

Zentalis Pharmaceuticals, Inc. valuation and forecast

Explore the models for Zentalis Pharmaceuticals, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Zentalis Pharmaceuticals, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

11 analysts, Oct 2026
Buy873%
Hold327%
Sell00%

Monthly trend

  1. Oct 20268311
  2. Sep 20266511
  3. Aug 20265510
  4. Jul 20265510

Counts of recommendations published by analysts covering Zentalis Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

ZNTL valuation questions

How does Fundamentalytics value Zentalis Pharmaceuticals, Inc.?
We use the models that fit Zentalis Pharmaceuticals, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Zentalis Pharmaceuticals, Inc.